The use of brincidofovir for the treatment of mixed dsDNA viral infection.
Double-stranded DNA (dsDNA) viral infections constitute a major complication following solid organ and stem cell transplantation. Few therapeutic options are currently available for the treatment of such infections in highly immunocompromised hosts. Brincidofovir is an oral investigational drug with broad antiviral activity against dsDNA viruses in vitro, but clinical experience is limited. Here we report a young female who developed a mixed infection with adenovirus, cytomegalovirus, Epstein-Barr virus and BK polyomavirus after an allogeneic stem cell transplant, and was successfully treated with brincidofovir.
['Camargo|Jose F|JF|', 'Morris|Michele I|MI|', 'Abbo|Lilian M|LM|', 'Simkins|Jacques|J|', 'Saneeymehri|Seyyedeh|S|', 'Alencar|Maritza C|MC|', 'Lekakis|Lazaros J|LJ|', 'Komanduri|Krishna V|KV|']
D000328:Adult D000998:Antiviral Agents D001739:BK Virus D060085:Coinfection D003587:Cytomegalovirus D003596:Cytosine D004266:DNA Virus Infections D017809:Fatal Outcome D005260:Female D004854:Herpesvirus 4, Human D006801:Humans D016867:Immunocompromised Host D063065:Organophosphonates D033581:Stem Cell Transplantation D019562:Viral Load D055815:Young Adult
Brincidofovir Adenovirus Cytomegalovirus BK virus CMX001 Epstein–Barr virus